• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

法国社区获得性肺炎相关成本。

Costs associated with community acquired pneumonia in France.

机构信息

ESSEC Business School, Avenue Bernard Hirsch, 95021, Cergy-Pontoise Cedex, France.

CH d'Annecy Genevois, Annecy, France.

出版信息

Eur J Health Econ. 2018 May;19(4):533-544. doi: 10.1007/s10198-017-0900-z. Epub 2017 May 25.

DOI:10.1007/s10198-017-0900-z
PMID:28547724
Abstract

OBJECTIVES

Pneumocost is a prospective study that aimed at documenting the costs of the management of patients hospitalized with a pneumococcal pneumonia and the post-discharge costs during a 6-month period in the French context.

METHODS

Billing data were used to document hospital costs. Resource use during the follow-up period was collected through phone interviews at month 1, 3 and 6. Descriptive statistics and multivariate analyses were performed. We used generalized linear models with log-link functions to estimate parameters associated with hospital and follow-up costs of patients.

RESULTS

Five hundred twenty-four patients were enrolled in 40 public centers from October 2011 to April 2014. Average age was 63 (SD 17); 55.0% of them were male. Average length of stay was 15 days (SD 23). Average cost of stay for the French Sickness Fund was €7293 (SD €7363). Average cost of follow-up was €1242 (SD €3000) and decreased steadily through time. When controlling for patient's socioeconomic characteristics, severity of disease and hospital stay, results showed a concave relationship between hospital costs and age. Obesity, the severity of the disease and comorbidities were associated with constantly increasing inpatient costs. Concerning follow-up costs, we found the same concave relationship with age, while gender, a history of pneumonia and severity of the disease were the most important predictors of high costs after discharge.

CONCLUSION

Pneumocost is the first French study providing a robust estimation of the cost of managing invasive pneumococcal pneumonia in the French context.

摘要

目的

Pneumocost 是一项前瞻性研究,旨在记录法国住院治疗肺炎链球菌性肺炎患者的管理成本,以及 6 个月随访期内的出院后成本。

方法

使用计费数据记录住院费用。通过在第 1、3 和 6 个月的电话访谈收集随访期间的资源使用情况。采用描述性统计和多元分析。我们使用具有对数链接函数的广义线性模型来估计与患者住院和随访费用相关的参数。

结果

2011 年 10 月至 2014 年 4 月,40 家公立中心共纳入 524 例患者。平均年龄为 63(SD 17)岁;55.0%为男性。平均住院时间为 15 天(SD 23)。法国疾病基金的平均住院费用为 7293 欧元(SD 7363)。平均随访费用为 1242 欧元(SD 3000),且随时间稳步下降。在控制患者的社会经济特征、疾病严重程度和住院时间后,结果显示住院费用与年龄之间呈凹性关系。肥胖、疾病严重程度和合并症与住院费用持续增加有关。关于随访费用,我们发现与年龄也存在相同的凹性关系,而性别、肺炎病史和疾病严重程度是出院后费用高的最重要预测因素。

结论

Pneumocost 是第一项在法国背景下提供侵袭性肺炎链球菌性肺炎管理成本的稳健估计的法国研究。

相似文献

1
Costs associated with community acquired pneumonia in France.法国社区获得性肺炎相关成本。
Eur J Health Econ. 2018 May;19(4):533-544. doi: 10.1007/s10198-017-0900-z. Epub 2017 May 25.
2
Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia.社区获得性肺炎患者住院时间与护理费用之间的关系。
Am J Med. 2000 Oct 1;109(5):378-85. doi: 10.1016/s0002-9343(00)00500-3.
3
CAPECO: Cost evaluation of community acquired pneumonia managed in primary care.CAPECO:初级保健中社区获得性肺炎的成本评估。
Vaccine. 2016 Apr 27;34(19):2275-80. doi: 10.1016/j.vaccine.2016.03.013. Epub 2016 Mar 12.
4
Hospitalization costs for community-acquired pneumonia in Dutch elderly: an observational study.荷兰老年人社区获得性肺炎的住院费用:一项观察性研究。
BMC Infect Dis. 2016 Sep 2;16(1):466. doi: 10.1186/s12879-016-1783-9.
5
Health related quality of life in patients with community-acquired pneumococcal pneumonia in France.法国社区获得性肺炎患者的健康相关生活质量。
Health Qual Life Outcomes. 2018 Feb 2;16(1):28. doi: 10.1186/s12955-018-0854-6.
6
Length of stay after reaching clinical stability drives hospital costs associated with adult community-acquired pneumonia.达到临床稳定后的住院时间决定了与成人社区获得性肺炎相关的医院成本。
Scand J Infect Dis. 2013 Mar;45(3):219-26. doi: 10.3109/00365548.2012.726737. Epub 2012 Oct 31.
7
Observed costs and health care use of children in a prospective cohort study on community-acquired pneumonia in Geneva, Switzerland.瑞士日内瓦一项关于社区获得性肺炎的前瞻性队列研究中儿童的观察性成本和医疗保健使用情况。
Swiss Med Wkly. 2014 Apr 2;144:w13925. doi: 10.4414/smw.2014.13925. eCollection 2014.
8
Outcomes and costs among seniors requiring hospitalization for community-acquired pneumonia in Alberta.阿尔伯塔省因社区获得性肺炎需住院治疗的老年人的治疗结果及费用
J Am Geriatr Soc. 2004 Jan;52(1):31-8. doi: 10.1111/j.1532-5415.2004.52007.x.
9
Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.估算美国社区获得性肺炎患者住院时间缩短半天所产生的经济影响。
Curr Med Res Opin. 2009 Sep;25(9):2151-7. doi: 10.1185/03007990903102743.
10
Private costs of patients hospitalized with community-acquired pneumonia.社区获得性肺炎住院患者的个人费用。
Can Respir J. 2005 May-Jun;12(4):205-8. doi: 10.1155/2005/905970.

引用本文的文献

1
Prevention of pneumococcal infections: Impact of structured medico-pharmaceutical collaborative management to improve vaccination coverage of at-risk patients (OPTIVACC study): Protocol for a multicenter randomized stepped -wedge study.肺炎球菌感染的预防:结构化药物协作管理对提高高危患者疫苗接种覆盖率的影响(OPTIVACC研究):一项多中心随机阶梯楔形研究方案
Contemp Clin Trials Commun. 2025 Feb 15;44:101462. doi: 10.1016/j.conctc.2025.101462. eCollection 2025 Apr.
2
Hospital Burden of All-Cause Pneumonia and Nonbacteremic Pneumococcal Pneumonia in Adults in France Between 2013 and 2019.2013年至2019年间法国成人全因性肺炎和非菌血症性肺炎的医院负担
Open Forum Infect Dis. 2024 Jun 28;11(7):ofae349. doi: 10.1093/ofid/ofae349. eCollection 2024 Jul.
3

本文引用的文献

1
Hospitalization costs for community-acquired pneumonia in Dutch elderly: an observational study.荷兰老年人社区获得性肺炎的住院费用:一项观察性研究。
BMC Infect Dis. 2016 Sep 2;16(1):466. doi: 10.1186/s12879-016-1783-9.
2
Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions.患有基础疾病者侵袭性肺炎球菌病和肺炎的发病率及费用
BMC Health Serv Res. 2016 May 13;16:182. doi: 10.1186/s12913-016-1432-4.
3
Longitudinal DRG-based survey of all-cause and pneumococcal pneumonia and meningitis for inpatients in France (2005-2010).
Cost of illness of the vaccine-preventable diseases influenza, herpes zoster and pneumococcal disease in France.法国流感、带状疱疹和肺炎球菌病等疫苗可预防疾病的疾病成本。
Eur J Public Health. 2024 Feb 5;34(1):170-175. doi: 10.1093/eurpub/ckad212.
4
Delayed diagnosis of pneumonia in the emergency department: factors associated and prognosis.急诊科肺炎的延迟诊断:相关因素及预后
Front Med (Lausanne). 2023 May 12;10:1042704. doi: 10.3389/fmed.2023.1042704. eCollection 2023.
5
The impact of comorbidities and their stacking on short- and long-term prognosis of patients over 50 with community-acquired pneumonia.合并症及其堆积对 50 岁以上社区获得性肺炎患者短期和长期预后的影响。
BMC Infect Dis. 2021 Sep 14;21(1):949. doi: 10.1186/s12879-021-06669-5.
6
The 13-Valent Pneumococcal Conjugate Vaccine Elicits Serological Response and Lasting Protection in Selected Patients With Primary Humoral Immunodeficiency.13价肺炎球菌结合疫苗在部分原发性体液免疫缺陷患者中引发血清学反应并提供持久保护。
Front Immunol. 2021 Jul 5;12:697128. doi: 10.3389/fimmu.2021.697128. eCollection 2021.
7
Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs.法国需要入住 ICU 的肺炎球菌性肺炎负担:1 年预后、资源利用和成本。
Crit Care. 2021 Jan 10;25(1):24. doi: 10.1186/s13054-020-03442-z.
8
Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium.比利时 50 岁以上成年人肺炎球菌疫苗的经济评价。
Hum Vaccin Immunother. 2018 May 4;14(5):1218-1229. doi: 10.1080/21645515.2018.1428507. Epub 2018 Feb 22.
9
Health related quality of life in patients with community-acquired pneumococcal pneumonia in France.法国社区获得性肺炎患者的健康相关生活质量。
Health Qual Life Outcomes. 2018 Feb 2;16(1):28. doi: 10.1186/s12955-018-0854-6.
法国(2005-2010 年)住院患者全因死亡率和肺炎球菌性肺炎及脑膜炎的基于 DRG 的纵向调查。
Med Mal Infect. 2015 Nov-Dec;45(11-12):446-55. doi: 10.1016/j.medmal.2015.10.004. Epub 2015 Nov 20.
4
A comparative public health and budget impact analysis of pneumococcal vaccines: The French case.肺炎球菌疫苗的公共卫生与预算影响比较分析:以法国为例
Hum Vaccin Immunother. 2015;11(9):2188-97. doi: 10.1080/21645515.2015.1011957. Epub 2015 Aug 12.
5
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.多糖结合疫苗预防成人肺炎球菌性肺炎。
N Engl J Med. 2015 Mar 19;372(12):1114-25. doi: 10.1056/NEJMoa1408544.
6
Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe.西欧常规儿童免疫规划之外的肺炎球菌免疫接种建议。
Adv Ther. 2014 Oct;31(10):1011-44. doi: 10.1007/s12325-014-0157-1. Epub 2014 Oct 10.
7
Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH study.欧洲社区获得性肺炎住院患者的资源利用:REACH 研究分析。
BMC Pulm Med. 2014 Mar 5;14:36. doi: 10.1186/1471-2466-14-36.
8
Risk factors for community-acquired pneumonia in adults in Europe: a literature review.欧洲成人社区获得性肺炎的危险因素:文献综述。
Thorax. 2013 Nov;68(11):1057-65. doi: 10.1136/thoraxjnl-2013-204282.
9
Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥50 years.50 岁及以上商业保险美国成年人中按年龄和风险划分的社区获得性肺炎发作费用。
Appl Health Econ Health Policy. 2013 Jun;11(3):251-8. doi: 10.1007/s40258-013-0026-0.
10
Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.丹麦和瑞典 10 价与 13 价肺炎球菌结合疫苗的成本效益分析。
Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006. Epub 2013 Jan 10.